IRD Opus Genetics, Inc.

Price Chart

Executive Summary

Opus Genetics filed an S-3 registration statement to register up to 2,678,570 shares of common stock for resale by selling stockholders (Oberland Capital entities). The shares consist of 1,116,070 shares already issued at $4.48/share and up to 1,562,500 shares issuable upon conversion of up to 10% of the principal amount of $105M in convertible notes (conversion price $6.72). The company receives no proceeds from this resale registration, which fulfills a contractual covenant from the April 2026 Stock Purchase and Conversion Agreement. The filing itself is a routine contractual shelf registration, but the context of a recent $35M note tranche issuance and the company's pre-revenue clinical-stage status with a $378M market cap creates overhang risk.

Key Financial Metrics

Actionable Insight

Key Facts

• Registers up to 2,678,570 shares for resale by selling stockholders (Oberland Capital entities)
• Includes 1,116,070 shares already issued at $4.48/share and up to 1,562,500 shares issuable upon note conversion at $6.72/share
• Notes have aggregate committed principal amount of up to $105M; first tranche of $35M issued April 21, 2026
• Company receives no proceeds from this resale registration
• Stock closed at $4.12 on June 1, 2026, below the $4.48 purchase price and well below the $6.72 conversion price
• 82,565,835 shares outstanding as of May 31, 2026; potential dilution from this registration is ~3.2% of current shares
• Company is a clinical-stage biopharma with no significant revenue and expects continued losses
• Historical performance on IRD reports shows poor win rate (14% T+20) and negative average alpha (-17.16%)

Financial Impact

Up to 2,678,570 shares registered for resale, representing ~3.2% dilution relative to current 82.6M shares outstanding. At $4.12/share (June 1 close), the registered shares have a market value of ~$11M.

Risk Factors

• Resale of registered shares by Oberland Capital could pressure the stock price
• Stock trading at $4.12 is below the $4.48 purchase price and well below the $6.72 conversion price, suggesting potential further downside
• Company is pre-revenue with ongoing losses and will need additional capital, potentially through further dilutive offerings
• Additional note tranches (up to $105M total) could increase conversion shares beyond the 1.56M registered here
• Massive existing overhang from 21.15M warrants, 16.01M pre-funded warrants, and 7.89M stock options

Market Snapshot

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

US Market Status